Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 113-118

  Ascher Svanum, Haya ^a   Brnabic, Alan J M ^a   Lawson, Anthony H ^a   Kinon, Bruce J ^a   Stauffer, Virginia L ^a   Feldman, Peter D ^a   Kelin, Katarina ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Augmentation; Drug substitution; Polypharmacy; Schizophrenia; Switching

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFECT SIZE; EUROPEAN QUALITY OF LIFE INDEX; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENTAL FUNCTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PHYSICIAN ATTITUDE; POST HOC ANALYSIS; PREVALENCE; SAMPLE SIZE; SCHIZOPHRENIA; SHORT FORM 12; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84930479535     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S30268     Document Type: Article

References (24)

1. Correll CU. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? J Clin Psychiatry. 2008;69(4):674-675.
2. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68(Suppl 1):S12-S19.
3. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
4. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2): 269-284.
5. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500-508.
6. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383-399.
7. Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract. 2008;14(6): 345-367.
8. Taylor D, Mir S, Mace S, et al. Co-prescribing of atypical and typical antipsychotics-prescribing sequence and documented outcome. Psychiatr Bull. 2002;26:170-172.
9. Kelin K, Lambert TJ, Brnabic AJ, et al. Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence. 2011;5:213-222.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976.
11. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233.
12. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
13. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183.
14. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150(6): 873-879.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
16. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1969.
17. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm. 2002;59(22 Suppl 8):S22-S26.
18. Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry. 2005;38(3):122-124.
19. Tsutsumi C, Uchida H, Suzuki T, et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr Res. 2011;130(1-3):40-46.
20. Ayuso-Gutiérrez JL, del Río Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28(2-3): 199-206.
21. Lindström E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics. 2000;18(2):106-124.
22. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67(3):453-460.
23. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990-996.
24. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.